Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 10,553 matching trials from the live ClinicalTrials.gov search.

Filters: Cincinnati, Ohio Clear all

Conditions: Acne Vulgaris
Interventions: 50 mg P005672-HCl, Placebo, 100 mg P005672-HCl; Drug
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 12 Years to 45 Years
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 38
States / cities: Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 34 more

Conditions: Food Insecurity
Interventions: In-hospital food support intervention, Post-discharge food support intervention; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 21 Years
Enrollment: 9,119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Rheumatoid Arthritis
Interventions: tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 54
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more

Conditions: Heart Failure
Interventions: Edwards APTURE transcatheter shunt system; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2032
U.S. locations: 19
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: Prevention of Rejection in Kidney Transplant
Interventions: AT-1501; Drug
Lead sponsor: Eledon Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Fibromyalgia
Interventions: DS-5565, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 22
States / cities: Phoenix, Arizona • Colton, California • Los Angeles, California + 19 more

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab, Laser; Drug · Procedure
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: Up to 6 Months
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 32
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Irvine, California + 26 more

Conditions: Glioblastoma
Interventions: Edotecarin, Temozolomide, Carmustine (BCNU), Lomustine (CCNU); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 19
States / cities: Phoenix, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 16 more

Conditions: Progressive Pulmonary Fibrosis
Interventions: BMS-986278, BMS-986278 Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years and older
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 81
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 70 more

Conditions: Idiopathic Hypersomnia
Interventions: TAK-360, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: Redwood City, California • Santa Ana, California • Colorado Springs, Colorado + 9 more

Conditions: Atopic Dermatitis
Interventions: Barzolvolimab, Matching placebo; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 33
States / cities: Birmingham, Alabama • Beverly Hills, California • Burbank, California + 28 more

Conditions: HIV Infections, Cervix, Dysplasia
Interventions: Fluorouracil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 19
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 13 more

Conditions: Metastatic Castration-resistant Prostatic Neoplasms
Interventions: Pasritamig, Placebo, Best Supportive Care (BSC), JNJ-87189401; Biological · Other · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 55
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 43 more

Conditions: Hepatocellular Carcinoma, Cirrhosis, Portal Hypertension
Interventions: Durvalumab, Tremelimumab, Liver Transplant; Drug · Procedure
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: St Louis, Missouri • Cincinnati, Ohio • Dallas, Texas

Conditions: Hepatitis C
Interventions: CTS-1027, Pegylated interferon, Ribavirin; Drug
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: La Jolla, California • San Diego, California • Denver, Colorado + 10 more

Conditions: Sickle Cell Disease, Measles Vaccination, Sickle Cell Anemia
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Months to 6 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Pemetrexed, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1081
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 694 more

Conditions: Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions: ALN-PCSSC, Normal Saline; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more

Conditions: Migraine
Interventions: Placebo ZNS, ZNS; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 47
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 38 more

Conditions: Aphakia, Presbyopia
Interventions: CPO Pro IOL, CPO IOL, Cataract Surgery; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 22 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Torrance, California • Bloomfield Hills, Michigan • Kansas City, Missouri + 5 more

Conditions: Cytomegalovirus (CMV)
Interventions: Maribavir; Drug
Lead sponsor: Takeda; Industry
Eligibility: Up to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Wilmington, Delaware • St. Petersburg, Florida • Chicago, Illinois + 4 more

Conditions: Covid19
Interventions: Ivermectin, Placebo; Drug · Other
Lead sponsor: Susanna Naggie, MD; Other
Eligibility: 30 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 87
States / cities: Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more

Conditions: Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions: mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo; Drug
Lead sponsor: Astellas Pharma Europe Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 36
States / cities: Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more

Conditions: Prostate Cancer
Interventions: 3D-CRT; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,084 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2013
U.S. locations: 213
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more

Search by objective public record fields.

Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris

Food-based Support for Hospitalized Children and Their Families

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

Early Feasibility Study - Edwards APTURE Transcatheter Shunt System

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease

A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP

Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

A Study of Barzolvolimab in Patients With Atopic Dermatitis

A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders

Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE

Clareon PanOptix Pro vs. Clareon PanOptix - Study B

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer